NL-OMON40957已完成2 期
A B2-agonist as a CFTR activator in CF - ABBA-study
niversitair Medisch Centrum Utrecht0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Signed informed consent form (ICF);
- •* Males and females, aged 18 years or older on the date of informed consent;
- •* CFTR genotype compound/A455E or compound/R117H.
排除标准
- •* Severe acute exacerbation or pulmonary infection (needing intravenous treatment and/or systemic corticosteroids);
- •* Uncontrolled CF related Diabetes;
- •* Participation in another drug-investigating clinical study at the start or within 1 month prior to the start;
- •* Treatment with B2 agonist at the start of the study or a week prior to the start of the study;
- •* Inability to follow instructions of the investigator;
- •* Increased risk on side-effects of Salbutamol
- •* Use of medication that are known to potentially interact with Salbutamol
- •* (Potential) pregnancy or breastfeeding.
研究者
相似试验
进行中（未招募）
1 期
Bronchodilcation as a CFTR activator in CFCystic FibrosisEUCTR2014-000057-37-NLniversity Medical Centre Utrecht
尚未招募
不适用
A B2-agonist as a CFTR activator in CF Part IICystic FibrosisNL-OMON24538niversity Medical Center Utrecht20
进行中（未招募）
1 期
A B2-agonist as a CFTR activator in CF - Part 2Cystic fibrosisEUCTR2015-001317-28-NLMC Utrecht
已完成
不适用
A B2-agonist as a CFTR activator in CFCFTR residual function, Salbutamol, CFTR activation, personalized medicineNL-OMON21450MCU Utrecht, Prof. dr. C.K. van der Ent10
已完成
2 期
A B2-agonist as a CFTR activator in CF - Part 210083624Cystic FibrosisMucoviscidosisNL-OMON43663niversitair Medisch Centrum Utrecht14